Supercharged immune cells take on advanced liver cancer

NCT ID NCT06902389

Recruiting now Disease control Sponsor: Eastern Hepatobiliary Surgery Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new immune cell therapy called Super Hi-TCR-T cells in 30 people with advanced liver cancer that has not responded to standard treatments. The cells are designed to attack multiple targets on cancer cells. Participants receive the cells after a short chemotherapy course. The goal is to see if the treatment is safe and can slow or stop cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Super Hi-TCR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced liver cancer that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The therapy involves chemotherapy pretreatment and carries risks like immune reactions or side effects from the cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

The Third Affiliated Hospital of Navy Military Medical University
RECRUITING

Shanghai, Yangpu District, 200438, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.